Influence of omeprazole on pharmacokinetics of domperidone given as free base and maleate salt in healthy Chinese patients

Acta Pharmacologica Sinica

Volumn 28, Issue 8, 2007, Pages 1243-1246

  Zhang, Yi Fan ^a   Chen, Xiao Yan ^a   Dai, Xiao Jian ^a   Zhang, Yi Ni ^a,b   Liu, Qi Zhi ^c   Yu, Hua Ling ^b   Zhong, Da Fang ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^c Beijing Hanmi Pharm   (China)

Author keywords

Domperidone; Free base; Maleate salt; Omeprazole; Pharmacokinetics

Indexed keywords

DOMPERIDONE; MALEIC ACID; OMEPRAZOLE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG FORMULATION; HUMAN; LIQUID CHROMATOGRAPHY; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY;

ADULT; ANTI-ULCER AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DOMPERIDONE; DOPAMINE ANTAGONISTS; DRUG INTERACTIONS; HUMANS; MALE; OMEPRAZOLE;

EID: 34547556795     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2007.00596.x     Document Type: Article

References (13)

1. Rowland M, Tozer TN. Clinical pharmacokinetics, concepts and applications. Philadelphia, USA : Lippincott Williams & Wilkins 1995.
2. Hatlebakk JG, Berstad A. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. Clin Pharmacokinet 1996 31 : 386 406.
3. Huang YC, Colaizzi JL, Bierman RH, Woestenborghs R, Heykants JJ. Pharmacokinetics and dose proportionality of domperidone in healthy volunteers. J Clin Pharmacol 1986 26 : 628 32.
4. Barone JA. Domperidone: a peripherally acting dopamine 2-receptor antagonist. Ann Pharmacother 1999 33 : 429 40.
5. Jiang SP, Liang RY, Zeng ZY, Liu QL, Liang YK, Li JG. Effects of antireflux treatment on bronchial hyper-responsiveness and lung function in asthmatic patients with gastroesophageal reflux disease. World J Gastroenterol 2003 9 : 1123 5.
6. Yu HL, Chen XY, Zhong DF. Determination of domperidone in human plasma by liquid chromatography-tandem spectrometry J Instrument Anal 2005 24 Suppl 5 : 149 50. Chinese.
7. Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS. Domperidone, a review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs 1982 24 : 360 400.
8. Gan KH, Geus WP, Lamers CB, Heijerman HG. Effect of omeprazole 40 mg once daily on intraduodenal and intragastric pH in H. pylori-negative healthy subjects. Dig Dis Sci 1997 42 : 2304 9.
9. Cederberg C, Rohss K, Lundborg P, Olbe L. Effect of once daily intravenous and oral omeprazole on 24-hour intragastric acidity in healthy subjects. Scand J Gastroenterol 1993 28 : 179 84.
10. Hartmann M, Theiss U, Huber R, Luhmann R, Bliesath H, Wurst W, et al. Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment Pharmacol Ther 1996 10 : 359 66.
11. Graham DY, Opekun AR, Jogi M, Yamaoka Y, Lu H, Reddy R, et al. False negative urea breath tests with H2-receptor antagonists: interactions between Helicobacter pylori density and pH. Helicobacter 2004 9 : 17 27.
12. Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004 32 : 821 7.
13. Simard C, Michaud V, Gibbs B, Masse R, Lessard E, Turgeon J. Identification of the cytochrome P450 enzymes involved in the metabolism of domperidone. Xenobiotica 2004 34 : 1013 23.